322 results on '"Tennekoon, Gihan"'
Search Results
2. Disease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension trial
Catalog
Books, media, physical & digital resources
3. MR biomarkers predict clinical function in Duchenne muscular dystrophy
4. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
5. Retrospective Analysis of Fractures and Factors Causing Ambulation Loss After Lower Limb Fractures in Duchenne Muscular Dystrophy
6. Modeling disease trajectory in Duchenne muscular dystrophy
7. A Role for Pak Protein Kinases in Schwann Cell Transformation
8. Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG)
9. Two-Year Longitudinal Changes in Lower Limb Strength and Its Relation to Loss in Function in a Large Cohort of Patients With Duchenne Muscular Dystrophy
10. Quantitative Evaluation of Lower Extremity Joint Contractures in Spinal Muscular Atrophy: Implications for Motor Function
11. Juvenile-onset motor neuron disease caused by novel mutations in β-hexosaminidase
12. Childhood Multiple Sclerosis: A Review
13. Step Activity Monitoring in Boys with Duchenne Muscular Dystrophy and its Correlation with Magnetic Resonance Measures and Functional Performance
14. Development of Contractures in DMD in Relation to MRI-Determined Muscle Quality and Ambulatory Function
15. Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort
16. Meta-analyses of deflazacort versus prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy
17. SPINAL MUSCULAR ATROPHY FUNCTIONAL COMPOSITE SCORE: A FUNCTIONAL MEASURE IN SPINAL MUSCULAR ATROPHY
18. Association of a Novel ACTA1 Mutation With a Dominant Progressive Scapuloperoneal Myopathy in an Extended Family
19. Homophilic Adhesion of the Myelin Po Protein Requires Glycosylation of Both Molecules in the Homophilic Pair
20. Transfection of Neonatal Rat Schwann Cells with SV-40 Large T Antigen Gene under Control of the Metallothionein Promoter
21. Cerebroside Sulfotransferase: Preparation of Antibody and Localization of Antigen in Kidney
22. Topography of Cerebroside Sulfotransferase in Golgi-Enriched Vesicles from Rat Brain
23. Myelinogenesis in Optic Nerve. A Morphological, Autoradiographic, and Biochemical Analysis
24. Choline Acetyltransferase Activity in Striatum of Neonatal Rats Increased by Nerve Growth Factor
25. Psychometric properties of the PEDI-CAT for children and youth with spinal muscular atrophy
26. MLIP causes recessive myopathy with rhabdomyolysis, myalgia and baseline elevated serum creatine kinase
27. Spectrum of Neuropathophysiology in Spinal Muscular Atrophy Type I
28. Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy
29. Notch and Schwann cell transformation
30. Walking activity in a large cohort of boys with Duchenne muscular dystrophy
31. Upper and Lower Extremities in Duchenne Muscular Dystrophy Evaluated with Quantitative MRI and Proton MR Spectroscopy in a Multicenter Cohort
32. One-Time Intrathecal (IT) Administration of AVXS-101 IT Gene-Replacement Therapy for Spinal Muscular Atrophy: Phase 1 Study (STRONG) (2493)
33. Central nervous system hyperexcitability associated with glutamate dehydrogenase gain of function mutations
34. Myelin Po-protein, more than just a structural protein?
35. Lysophosphatidic Acid Promotes Survival and Differentiation of Rat Schwann Cells
36. MLIP causes recessive myopathy with rhabdomyolysis, myalgia and baseline elevated serum creatine kinase.
37. Dominant collagen XII mutations cause a distal myopathy
38. Edasalonexent, an NF-kB Inhibitor, Slows Longer-Term Disease Progression on Multiple Functional and MRI Assessments Compared to Control Period in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy (S51.006)
39. Phase 1 Study of Intrathecal Administration of AVXS-101 Gene-Replacement Therapy (GRT) for Spinal Muscular Atrophy Type 2 (SMA2) (STRONG) (P1.6-059)
40. Characterization of Insulin-Like Growth Factor-I and Its Receptor and Binding Proteins in Transected Nerves and Cultured Schwann Cells
41. Dominant collagen XII mutations cause a distal myopathy
42. Neuregulin Signaling through a PI3K/Akt/Bad Pathway in Schwann Cell Survival
43. Walking activity in a large cohort of boys with Duchenne muscular dystrophy.
44. Nusinersen versus sham control in later-onset spinal muscular atrophy
45. Longitudinal timed function tests in Duchenne muscular dystrophy: ImagingDMD cohort natural history
46. Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy
47. Longitudinal timed function tests in Duchenne muscular dystrophy: ImagingDMD cohort natural history
48. Ambulatory function in spinal muscular atrophy: Age-related patterns of progression
49. Evaluator Training and Reliability for SMA Global Nusinersen Trials1
50. MoveDMD®: Positive Effects of Edasalonexent, an NF-κB Inhibitor, in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy in Phase 2 Study with an Open-Label Extension (S29.006)
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.